<DOC>
	<DOCNO>NCT01607905</DOCNO>
	<brief_summary>Phase 1 study evaluate safety tolerability KPT-330 determine Recommended Phase 2 Dose ( RP2D ) KPT- 330 advance metastatic solid tumor malignancy .</brief_summary>
	<brief_title>Safety Study KPT-330 Patients With Advanced Metastatic Solid Tumor Cancer</brief_title>
	<detailed_description>This phase 1a phase 1b , open-label , dose-escalation study evaluate safety tolerability KPT-330 determine RP2D patient solid tumor malignancy .</detailed_description>
	<criteria>1 . Dose Escalation Phase : Patients advance metastatic solid tumor standard therapy available . For Schedule 6 : patient colorectal cancer liver metastasis . Dose Expansion Phase : Previously treat , metastatic advance recurrent malignancy 1 follow diagnosis , confirm histologically cytologically : Up 12 patient metastatic colorectal cancer history progression recurrence follow prior fluoropyrimidine , irinotecan platinum contain regimen well bevacizumab . In addition , patient Kras wild type tumor must receive least one EGFR blocker . Up 6 patient histological cytological documentation advance ovarian , fallopian tube , primary peritoneal carcinoma history progression recurrence follow least one prior platinum one taxane base chemotherapy Up 12 patient incurable Squamous cell cancer follow : 1 . A minimum 4 Squamous NonSmall Cell Lung Cancer ( SqNSCLC ) 2 . A minimum 4 Squamous Cell Carcinomas Head Neck ( SqHNC ) 3 . Squamous Cell Carcinoma Cervix ( SqCC ) All patient Squamous Cell Carcinomas document history progression recurrence follow least one prior platinum base chemotherapy chemotherapy/radiation contain regimen Up 6 patient castrationresistant prostate cancer ( CRPC ) pathologically confirm adenocarcinoma prostate evidence metastatic disease bone scan imaging . Patient must progressive disease least one hormonal treatment one cytotoxic therapy e.g . docetaxel , mitoxantrone . Up 6 patient recurrent/relapsed glioblastoma multiforme ( GBM/AnaA ) grade 3 anaplastic astrocytomas history progression recurrence follow radiotherapy alkylating agent ( e.g . temozolomide ) Patients disease type may enrol expansion phase upon approval Sponsor . 2 . Dose Escalation Phase : Patients exhaust , deem benefit , conventional therapy evidence progressive disease study entry . Both Dose Escalation Expansion Phases : There upper limit number prior treatment provide inclusion criterion meet exclusion criterion meet . Hormone ablation therapy consider anticancer regimen . Radiation surgery consider anticancer regime . 1 . Radiation , chemotherapy , immunotherapy anticancer therapy â‰¤3 week prior cycle 1 day 1 mitomycin C radioimmunotherapy 6 week prior cycle 1 day 1 ; 2 . Except patient GBM/ AnaA Expansion Phase , patient active CNS malignancy exclude . Asymptomatic small lesion consider active . Treated lesion may consider inactive stable least 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Melanoma</keyword>
</DOC>